Reported Sunday, Nov 1 - 7:16pm EST (TheFly subscription required to read more.)

AstraZeneca reported that Tagrisso plus Orpathys extended progression-free and overall survival in MET-driven EGFR-mutated lung cancer after Tagrisso.

HUTCHMED (China) said on Tuesday ​that Anglo-Swedish drugmaker AstraZeneca ‌had applied to the US Food and Drug Administration for approval of the ORPATHYS-TAGRISSO ​combination to treat patients with advanced ​lung cancer.

Reported Tuesday, Sep 1 - 6:37am EDT (TheFly subscription required to read more.)

The Phase III SANOVO trial showed Tagrisso plus Orpathys significantly improved progression-free survival in treatment-naïve, MET-overexpressing EGFR-mutated lung cancer patients, extending the combination's reach into first-line treatment.

AstraZeneca reported positive results from two non-small cell lung cancer trials for Enhertu and an Orpathys-Tagrisso combination, although the dual wins provided little cover for the company amid | AstraZeneca reported phase 3 lung cancer wins for Enhertu and a combination of Orpathys and Tagrisso, but the victories were eclipsed by the failure of its PD-1/CTLA-4 bispecific antibody in a simultan

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED “) (Nasdaq/AIM: HCM; HKEX: 13) today announces positive high-level results from the SANOVO China Phase III trial in treatment-naïve patients with locally advanced or metastatic non-small cell lung cancer (“NSCLC”) whose tumors harbor epidermal growth factor receptor (“EGFR”) mutation and MET overexpression.

AstraZeneca and Daiichi Sankyo reported that Enhertu (trastuzumab deruxtecan) met its primary endpoint in the DESTINY-Lung04 study, showing a clear and meaningful extension of progression-free surviva...

AstraZeneca and Daiichi Sankyo reported that Enhertu (trastuzumab deruxtecan) met its primary endpoint in the DESTINY-Lung04 study, showing a clear and meaningful extension of progression-free surviva...

AstraZeneca and Daiichi Sankyo reported that Enhertu (trastuzumab deruxtecan) met its primary endpoint in the DESTINY-Lung04 study, showing a clear and meaningful extension of progression-free surviva...

AstraZeneca and Daiichi Sankyo reported that Enhertu (trastuzumab deruxtecan) met its primary endpoint in the DESTINY-Lung04 study, showing a clear and meaningful extension of progression-free surviva...

The SAFFRON Phase III trial showed Tagrisso plus Orpathys significantly extended progression-free and overall survival in EGFR-mutated lung cancer patients who had progressed on Tagrisso alone.

Reported Sunday, Aug 16 - 8:20pm EDT (TheFly subscription required to read more.)

Hutchmed has completed subject enrolment in the Phase III SANOVO trial in China, of the combination of Orpathys and Tagrisso.

HUTCHMED has secured conditional approval from China’s National Medical Products Administration for savolitinib, marketed as Orpathys, in a new gastric cancer indication.The decision allows oncologist...